

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A method of reducing endotoxin induced cytokine production in a human patient suffering from cachexia or body wasting ~~treating or ameliorating body wasting or cachexia in a human patient with liver cirrhosis, chronic obstructive pulmonary disease, chronic renal failure, diabetes, rheumatoid arthritis in a patient~~ the method comprising administering to the human patient an effective amount of a compound that is able to reduce the production, *absorption and/or* the effect of an endotoxin (lipopolysaccharide; ~~LPS~~).

2. (Currently amended) A method according to claim 1, further comprising treating, preventing or ameliorating endotoxin-mediated immune activation in body wasting or cachexia in a human patient with liver cirrhosis, ~~chronic obstructive pulmonary disease, chronic renal failure, diabetes, rheumatoid arthritis~~ the method comprising administering to the human patient an effective amount of a compound that is able to reduce the production, absorption and/or the effect of an endotoxin (lipopolysaccharide; ~~LPS~~).

3. (Currently amended) A method according to claim 1 wherein the compound is able to bind to an endotoxin (lipopolysaccharide; ~~LPS~~) molecule.

4. (Previously presented) A method according to claim 1 wherein the compound is able to reduce *the* available endotoxin in the patient.

BEST AVAILABLE COPY

BEST AVAILABLE COPY

Attorney Docket: 101195-65

Amendment dated January 17, 2005

Response to Notice of Non-Compliant Amendment dated January 7, 2005

5. (Previously presented) A method according to claim 1 wherein the compound is a bile acid.

6. (Previously presented) A method according to claim 1 wherein the bile acid is any one of ursodesoxycholic acid, chenodeoxycholic acid, dehydrocholic acid, cholic acid and deoxycholic acid.

7. (Withdrawn) A method according to claim 1 wherein the compound is LPS binding protein.

8. (Withdrawn) A method according to claim 1 wherein the compound is bactericidal/permeability increasing protein (BPI).

9. (Withdrawn) A method according to claim 1 wherein the compound is, a lipoprotein, for instance, low density lipoprotein (LDL), high density lipoprotein (HDL), very low density lipoprotein (VLDL), apolipoprotein (a), a lipoprotein mixture.

10. (Withdrawn) A method according to claim 1 wherein the treatment is a combination of a compound according claim 7 and claim 9.

11. (Withdrawn) A method according to claim 1 wherein the compound is or an antibody capable of binding to endotoxin (lipopolysaccharide; LPS).

12. (Withdrawn) A method according to claim 1 wherein the compound is or an antibody capable of binding to endotoxin (lipopolysaccharide; LPS).

13. (Withdrawn)) A method according to claim 1 wherein the compound is an antibody able to bind to the CD14 receptor.

14. (Withdrawn) A method according to claim 1 wherein the compound is a soluble CD 14 receptor.

15. (Withdrawn) A method according to claim 1 wherein the compound is a drug blocking effectively signaling through toll-like receptors, for instance toll-like receptor 4 and toll-like receptor 2.

16. (Withdrawn) A method according to claim 1 wherein the compound is colostrum of human, bovine, or other mammalian origin.

17. (Withdrawn) A method according to claim 1 wherein the compound is able to inhibit the response by a cell to endotoxin (lipopolysaccharide; LPS).

18. (Withdrawn) A method according to claim 1 wherein the compound is able to decrease the cytokine production by a cell in response to endotoxin (lipopolysaccharide; LPS).

19. (Currently amended) A method according to claim 1 wherein the compound is a compound named in claim 5 to 16.

20. (Previously presented) A method according to claim 1 wherein the compound is administered orally.

21. (Previously presented) A method according to claim 1 wherein the compound is administered intravenously.

22. (Previously presented) A method according to claim 1 wherein the compound is administered rectally.

23. (Canceled)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.